Valuation
- Market cap
- 64,580,000
- Revenue TTM
- $570,000
- Net income TTM
- $-26,480,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,645.61%
- Debt to equity
- 0.00
Trading
- Volume
- 35,400
- Avg volume
- 90,547
- Day's range
- $22.49 – $23.98
- Shares out
- 2,670,000
- Stochastic %K
- 10%
- Beta
- 2.01
- Analysts
- Sell
- Price target
- $58.00
Company profile
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://www.yarrowbioscience.com
- Address
- 40 10 th Avenue, Floor 7, New York, United States
Latest news
No headlines yet.
